4D Molecular Therapeutics increases wet AMD trial enrollment to 480 patients for global regulatory submissions

4D Molecular Therapeutics, Inc.

Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 trials raised from 400 to 480 patients each.
Amendments aim for ~90% power with ~4-letter noninferiority margin for non-FDA agencies (e.g., PMDA, EMA).
No impact on guided enrollment completion or financial runway into H2 2028; 4FRONT-1 topline expected H1 2027.
Asia-Pacific regulatory submissions supported by Otsuka partnership, leveraging global commercial opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.